Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.

Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, Magarotto V, Tacchetti P, Pescosta N, Cellini C, Polloni C, Evangelista A, Caravita T, Morabito F, Offidani M, Tosi P, Boccadoro M.

J Clin Oncol. 2011 Mar 10;29(8):986-93. doi: 10.1200/JCO.2010.31.6844. Epub 2011 Jan 31.

PMID:
21282540
2.

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.

Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A.

Blood. 2012 Jan 26;119(4):933-9; quiz 1093. doi: 10.1182/blood-2011-03-344333. Epub 2011 Aug 11.

3.

[Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative].

Själander A, Wallentin L, Rosenqvist M, Svensson P.

Lakartidningen. 2008 Sep 10-16;105(37):2478-80. Swedish. No abstract available.

PMID:
19006862
4.

Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.

Alexander M, Teoh KC, Lingaratnam S, Kirsa S, Mellor JD.

Asia Pac J Clin Oncol. 2013 Jun;9(2):169-75. doi: 10.1111/ajco.12013. Epub 2012 Sep 24.

PMID:
22998589
5.

Thalidomide thromboprophylaxis in multiple myeloma: a review of current evidence.

Alexander M, Kirsa S, Mellor JD.

Asia Pac J Clin Oncol. 2012 Dec;8(4):319-24. doi: 10.1111/j.1743-7563.2011.01511.x. Epub 2012 Apr 23. Review.

PMID:
22897571
6.

Combined warfarin-aspirin therapy: what is the evidence for benefit and harm and which patients should (and should not) receive it?

Donadini MP, Douketis JD.

J Thromb Thrombolysis. 2010 Feb;29(2):208-13. doi: 10.1007/s11239-009-0413-4. Review.

PMID:
19915994
8.

Thrombosis in multiple myeloma.

Zangari M, Elice F, Fink L, Tricot G.

Expert Rev Anticancer Ther. 2007 Mar;7(3):307-15. Review.

PMID:
17338651
9.

Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.

Pauzner R, Dulitzki M, Langevitz P, Livneh A, Kenett R, Many A.

Thromb Haemost. 2001 Dec;86(6):1379-84.

PMID:
11776303
10.

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.

Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA.

Blood. 2006 Jul 1;108(1):403; author reply 404. No abstract available.

11.

Warfarin and aspirin as thromboprophylaxis in atrial fibrillation.

Lip GY, Lowe GD.

Br J Clin Pharmacol. 1996 May;41(5):369-79. Review.

12.

[Guidelines for antithrombotic therapy in atrial fibrillation: what the Italian Hemostasis and Thrombosis Society thinks].

Prisco D.

Haematologica. 2001 Sep;86(9 Suppl):12-3. Italian. No abstract available.

PMID:
11759618
13.

Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.

Palumbo A, Rus C, Zeldis JB, Rodeghiero F, Boccadoro M; Italian Multiple Myeloma Network, Gimema.

J Thromb Haemost. 2006 Aug;4(8):1842-5. No abstract available.

14.
15.

Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute.

Brulotte S, Sénéchal M, Poirier P, Nguyen CM, Lemieux A, Magne J, Bergeron S.

Can J Cardiol. 2007 Oct;23 Suppl B:80B-83B. Erratum in: Can J Cardiol. 2009 Mar;25(3):140.

16.

Thromboprophylaxis in multiple myeloma: is the evidence there?

Kristinsson SY, Landgren O.

Expert Rev Anticancer Ther. 2012 Mar;12(3):291-4. doi: 10.1586/era.11.214. No abstract available.

PMID:
22369320
17.

Safety and efficacy of enoxaparin treatment in venous thromboembolic disease during acute leukemia.

Imberti D, Vallisa D, Anselmi E, Moroni CF, Bertè R, Lazzaro A, Bernuzzi P, Arcari AL, Cavanna L.

Tumori. 2004 Jul-Aug;90(4):390-3.

PMID:
15510981
19.

Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma.

Singh A, Gajra A.

Cardiovasc Hematol Agents Med Chem. 2011 Jan;9(1):7-13. Review.

PMID:
20874693
20.

[Atrial fibrillation and thromboembolic events prevention. State of the art].

Matteoli S, Trappolini M, Chillotti FM.

Minerva Cardioangiol. 2001 Feb;49(1):1-13. Review. Italian.

PMID:
11279381

Supplemental Content

Support Center